NHC Key Laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, Jilin 130021, China.
Department of Toxicology, School of Public Health, Jilin University, Changchun, Jilin 130021, China.
Oxid Med Cell Longev. 2022 Aug 29;2022:7608712. doi: 10.1155/2022/7608712. eCollection 2022.
Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase involved in cell proliferation, invasion, angiogenesis, and metastasis in various cancers, including hepatocellular carcinoma (HCC). However, the role and molecular mechanisms of EZH2 in HCC radiosensitivity remain unclear. Here, we show that EZH2 is upregulated in HCC cells and the aberrantly overexpressed EZH2 is associated with the poor prognosis of HCC patients. Using miRNA databases, we identified miR-138-5p as a regulator of EZH2. We also found that miR-138-5p was suppressed by EZH2-induced H3K27me3 in HCC cell lines. MiR-138-5p overexpression and EZH2 knockdown enhanced cellular radiosensitivity while inhibiting cell migration, invasion, and epithelial-mesenchymal transition (EMT). Analysis of RNA-seq datasets revealed that the hypoxia-inducible factor-1 (HIF-1) signaling pathway was the main enrichment pathway for differential genes after miR-138-5p overexpression or EZH2 knockdown. Expression level of HIF-1 was significantly suppressed after miR-138-5p overexpression or silencing of EZH2. HIF-1 silencing mitigated resistance of HCC cells and inhibited EMT. This study establishes the EZH2/miR-138-5p/HIF-1 as a potential therapeutic target for sensitizing HCC to radiotherapy.
增强子结合锌指蛋白 2(EZH2)是一种组蛋白甲基转移酶,参与多种癌症的细胞增殖、侵袭、血管生成和转移,包括肝细胞癌(HCC)。然而,EZH2 在 HCC 放射敏感性中的作用和分子机制尚不清楚。在这里,我们表明 EZH2 在 HCC 细胞中上调,并且异常过表达的 EZH2与 HCC 患者的不良预后相关。使用 miRNA 数据库,我们鉴定出 miR-138-5p 是 EZH2 的调节剂。我们还发现,miR-138-5p 被 EZH2 诱导的 H3K27me3 在 HCC 细胞系中抑制。miR-138-5p 的过表达和 EZH2 的敲低增强了细胞的放射敏感性,同时抑制了细胞迁移、侵袭和上皮间质转化(EMT)。RNA-seq 数据集的分析显示,miR-138-5p 过表达或 EZH2 敲低后差异基因的主要富集途径是缺氧诱导因子-1(HIF-1)信号通路。HIF-1 的表达水平在 miR-138-5p 过表达或 EZH2 沉默后显著降低。HIF-1 的沉默减轻了 HCC 细胞的耐药性并抑制了 EMT。这项研究确立了 EZH2/miR-138-5p/HIF-1 作为增强 HCC 对放疗敏感性的潜在治疗靶点。